Biotech · Nasdaq
Gilead Sciences
Price data: TradingView widget below
Gilead Sciences (GILD) — Gilead develops medicines for HIV, liver disease, cancer and inflammation. Its HIV treatments are its biggest business.
Loading chart…
Open GILD chart in TradingView Affiliate: if you subscribe via our TradingView link, Hodlia may earn a commission at no extra cost to you.
Loading chart…
📐 Technicals
Loading chart…
Indicator summary from TradingView (moving averages, oscillators). A mechanical signal, not advice.
Open technicals in TradingView Affiliate: if you subscribe via our TradingView link, Hodlia may earn a commission at no extra cost to you.
📊 Fundamentals
Loading chart…
🏢 Company profile
Loading chart…
📰 Latest GILD news
Loading chart…
🧩 What it is
Gilead develops medicines for HIV, liver disease, cancer and inflammation. Its HIV treatments are its biggest business.
⚡ Why it's interesting
HIV medicines provide steady cash, and newer long-acting HIV prevention could add more. It pays a dividend.
⚠️ Key risks
It relies heavily on HIV products, patents eventually expire, and cancer acquisitions haven't always delivered. Drug-pricing reforms and trial failures are constant risks.
👀 What to watch
long-acting HIV prevention uptake, oncology results and patent cliffs. Steady cash with pockets of pipeline excitement and some disappointment. HIV prevention is the headline growth area, so launch numbers matter.
Written by the Hodlia.fi editorial team. Education only — not financial advice, no price predictions. Contains a TradingView affiliate link.
❓ Gilead Sciences FAQ
What is Gilead Sciences (GILD)?
Gilead develops medicines for HIV, liver disease, cancer and inflammation. Its HIV treatments are its biggest business.
Why do people follow Gilead Sciences?
HIV medicines provide steady cash, and newer long-acting HIV prevention could add more. It pays a dividend.
What are the main risks of Gilead Sciences?
It relies heavily on HIV products, patents eventually expire, and cancer acquisitions haven't always delivered. Drug-pricing reforms and trial failures are constant risks.
What should I watch with Gilead Sciences?
long-acting HIV prevention uptake, oncology results and patent cliffs. Steady cash with pockets of pipeline excitement and some disappointment. HIV prevention is the headline growth area, so launch numbers matter.
Is Gilead Sciences a good investment?
Hodlia không đưa ra tư vấn đầu tư. Gilead Sciences có phù hợp với bạn hay không phụ thuộc vào mục tiêu, khung thời gian và mức lỗ bạn chịu được. Cổ phiếu đơn lẻ có thể giảm mạnh ngay cả khi thị trường yên ắng. Hãy đọc rủi ro ở trên, so sánh với lựa chọn đa dạng hóa và cân nhắc tư vấn độc lập.